Refine
Year of publication
Document Type
- Article (30914)
- Part of Periodical (11931)
- Book (8324)
- Doctoral Thesis (5744)
- Part of a Book (3723)
- Working Paper (3394)
- Review (2879)
- Contribution to a Periodical (2369)
- Preprint (2325)
- Conference Proceeding (1710)
Language
- German (42638)
- English (30282)
- French (1067)
- Portuguese (723)
- Multiple languages (314)
- Croatian (302)
- Spanish (301)
- Italian (195)
- mis (174)
- Turkish (148)
Is part of the Bibliography
- no (76469) (remove)
Keywords
- Deutsch (1038)
- Literatur (809)
- taxonomy (771)
- Deutschland (543)
- Rezension (491)
- new species (457)
- Frankfurt <Main> / Universität (341)
- Rezeption (325)
- Geschichte (292)
- Übersetzung (271)
Institute
- Medizin (7813)
- Präsidium (5239)
- Physik (4765)
- Wirtschaftswissenschaften (2719)
- Extern (2661)
- Gesellschaftswissenschaften (2379)
- Biowissenschaften (2208)
- Biochemie und Chemie (1980)
- Frankfurt Institute for Advanced Studies (FIAS) (1875)
- Informatik (1716)
We describe a new minute species of the genus Pristimantis, P. boucephalus sp. nov., from the Yanachaga-Chemillén National Park, Región Pasco, Peru. The description is based on a freshly collected male specimen found at 2950 m a.s.l. in a cloud forest and four previously unidentified museum specimens consisting of two adult males, one subadult female and a juvenile from the Yanachaga-Chemillén National Park. The new species is mainly characterized by a snout–vent length of 13.4–14.5 mm in adult males (n = 3), and 12.5 mm in the only known subadult female, and is compared morphologically and genetically with other taxonomically and biogeographically relevant species of Pristimantis. The new species is characterized by its small size, disproportionally large head with short snout, absence of a tympanic annulus and membrane, and reddish-copper iris. Phylogenetically it belongs to a speciose clade, an as yet unnamed species group, comprising both montane (Andes, Guiana Shield) and lowland (Amazon) taxa from the northern part of South America. The new species is genetically close to the sympatric P. cruciocularis. Species of Pristimantis occurring in the Cordillera Yanachaga region in the Andes of central Peru are members of six divergent phylogenetic lineages.
Our lives (and deaths) have been dominated for more than a year by COVID-19, a pandemic that has caused hundreds of millions of disease cases, millions of deaths, trillions in economic costs, and major restrictions on our freedom. We argue that much of this could have been avoided by repeated and systematic population-scale PCR-based testing and targeted quarantine. We describe key elements of the current implementations of such a system and demonstrate (with Germany as an example), that this strategy could have suppressed the pandemic within weeks, eliminating the vast majority of its overall impact in terms of deaths, economic costs and restrictions. It can, however, still play a major role in further reducing the worldwide impact of the current phase of the pandemic, and remain as a key protection against similar dangers in the future.
Our lives (and deaths) have by now been dominated for two years by COVID-19, a pandemic that has caused hundreds of millions of disease cases, millions of deaths, trillions in economic costs, and major restrictions on our freedom. Here we suggest a novel tool for controlling the COVID-19 pandemic. The key element is a method for a population-scale PCR-based testing, applied on a systematic and repeated basis. For this we have developed a low cost, highly sensitive virus-genome-based test. Using Germany as an example, we demonstrate by using a mathematical model, how useful this strategy could have been in controlling the pandemic. We show using real-world examples how this might be implemented on a mass scale and discuss the feasibility of this approach.
Diese Diplomarbeit beschäftigt sich mit dem Entwurf und der Implementierung der Auslesefirmware für den GET4 Chip im Rahmen des CBM (Compressed Baryonic Matter) Experiments.
Physikalische Experimente mit Teilchenbeschleunigern, wie das geplante CBM Experiment, erzeugen große Mengen an Sensordaten, die aufbereitet, gespeichert und ausgewertet werden müssen. Der GET4 Chip ist ein möglicher TDC (Time to Digital Converter) Chip mit 4 Kanälen für den TOF (Time of Flight) Detektor des CBM Experiments. Der GET4 Chip erzeugt einen Zeitstempel für die Treffer der TOF RPC (Resistive Plate Chambers) Sensoren.
Die Auslese der GET4 Daten wird von einem ROC (Readout Controller Board) übernommen, das mit einem FPGA (Field Programmable Gate Array) ausgestattet ist. Das ROC Board lässt sich über die ROC Firmware für verschiedene Einsatzzwecke flexibel konfigurieren, so dass damit auch andere Frontend Elektronik, wie z.B. der n-XYTER Chip, ausgelesen werden kann. Während dieser Diplomarbeit wurde das SysCore2 mit einem Virtex-4 FX20 als ROC verwendet. Inzwischen ist das SysCore3 verfügbar, das einen deutlich leistungsfähigeren FPGA besitzt. Die bisher verfügbare Firmware für den GET4 war für den Betrieb im 24 Bit Modus konzipiert.
Der bevorzugte Auslesemodus für den GET4 ist der 32 Bit Modus, da der 24 Bit Modus einige Beschränkungen aufweist und die volle Funktionalität des GET4s nur im 32 Bit Modus zur Verfügung steht. Im Rahmen dieser Diplomarbeit wurde die vorhandene 24 Bit Firmware für den 32 Bit Modus erweitert, so dass der zweite Datenkanal des GET4s, sowie der DDR (Double Data Rate) Modus für die Datenübertragung zur Verfügung steht. Neben der Erhöhung der Datenübertragungsraten stand die mögliche Skalierbarkeit der Firmware für die Auslese möglichst vieler GET4 Chips im Fokus. Dazu musste die Firmware umgestaltet werden, um die begrenzten BRAM Ressourcen des FPGAs nicht unnötig zu belegen.
Eine weitere wichtige Neuerung der 32 Bit Firmware ist die automatische Synchronisation der Epochen zwischen ROC und GET4. Dazu werden die Epochennachrichten der GET4s mit der Epoche des ROCs verglichen und bei Bedarf Synchronisationsnachrichten mit der korrekten Epoche an die GET4s gesendet.
A Large Ion Collider Experiment (ALICE) is a high-energy physics experiment, designed to study heavy ion collisions at the European Organization for Nuclear Research (CERN)Large Hadron Collider (LHC). ALICE is built to study the fundamental properties of matter as it existed shortly after the big bang. This requires reading out millions of sensors with high frequency, enabling high statistics for physics analysis, resulting in a considerable computing demand concerning network throughput and processing power. With the ALICE Run 3 upgrade [14], requirements for a High Throughput Computing
(HTC) online processing cluster increased significantly, due to more than an order of magnitude more data than in Run 2, resulting in a processing input rate of up to 900 GB/s. Online (real-time) event reconstruction allows for the compression of the data stream to 130 GB/s, which is stored on disk for physics analysis.
This thesis presents the implementation of the ALICE Event Processing Node (EPN) compute farm, to cope with the Run 3 online computing challenges. Building a Data Centre tailored to ALICE requirements for the Run 3 and Run 4 EPN farm. Providing the operational conditions for a dynamic compute environment of a High Performance Computing (HPC) cluster, with significant load changes in a short time span, when starting or stopping a data-taking run. EPN servers provide the required computing resources for online reconstruction and data compression. The farm includes network connectivity towards First Level Processors (FLPs), requiring reliable throughput of 900 GB/s between FLPs and EPNs and connectivity from the internal InfiniBand network to the CERN Exabyte Object Storage (EOS) Ethernet network, with more than 100 GB/s.
The results of operating the EPN computing infrastructure during the first year of Run 3 LHC collisions are described in the context of the ALICE experiment. The EPN farm was delivering the expected performance for ALICE data-taking. Data Centre environmental conditions remained stable during the last more than two years, in particular during starting and stopping runs, which include significant changes in IT load. Several unforeseen external circumstances lead to increasing demands for the Online Offline System (O2). Higher data rates than anticipated required network performance to exceed the initial design specifications, for the throughput between FLPs and EPNs. In particular, the high throughput from an internal EPN InfiniBand network towards the storage Ethernet network was one of the challenges to overcome.
Background: There are no validated standardised clinical procedures for severity measurement of acute bronchitis in children. The "BSS-ped", a short version of the physician-rated assessment scale BSS (Bronchitis Severity Scale), can fill this gap, if it is valid.
Objective: To examine the scale´s validity.
Methods: Investigations were planned according to classical clinical-psychometric validity criteria including a formal competence evaluation of the scale´s authors and statistical analyses of data from 78 patients aged 1-6 and diagnosed with "acute bronchitis". Cross-validation was provided by analysis of data from 70 children with matching age, sex and diagnosis. All children were examined three times (day 0, 3-5 and 7) using the BSS-ped in addition to other clinical and psychometric monitoring procedures.
Results: The evidently high level of expertise of the scale’s authors substantiates pronounced content validity and relevance of the BSS-ped and its items. The validity criterion, i.e. to reflect the unidimensional severity of acute bronchitis and its change using the BSS-ped score, was fulfilled. There were substantial correlations with other scales measuring the current health-related quality of life, as well as satisfaction and success of treatment. Severity change prognoses for acute bronchitis under placebo and an active substance were correct. The BSS-ped was found to be a feasible instrument because it can be repeated at short intervals (minute range) without any special technical aids or extended training.
Conclusion: The BSS-ped is a valid procedure for measuring the severity of acute bronchitis in children.
Background: Standardization in clinical practice may lead to improved outcomes. Unfortunately, little is known about the variability of non-pharmacological anti-infective measures in children with cancer.
Design and Methods: A web-based survey assessed institutional recommendations regarding restrictions of social contacts, pets and food and instructions on wearing face masks in public for children with standard- risk acute lymphoblastic leuk emia and acute myeloid leukemia during intensive chemotherapy.
Results: A total of 336 institutions in 27 countries responded to the survey (range, 1-76 institutions per country; overall response rate 61%). Most institutions recommend that patients with acute myeloid leukemia avoid indoor public places and daycare, kindergarten and school, whereas recommendations for patients with acute lymphoblastic leukemia differ considerably by institution. In terms of restrictions related to pets, there was a wide variability between institutions for both acute lymphoblastic and acute myeloid leukemia patients. Most, but not all institutions do not allow children with either acute lymphoblastic or acute myeloid leukemia to eat raw meat, raw seafood or unpasteurized milk. Whereas most institutions do not routinely recommend that patients with acute lymphoblastic leukemia wear face masks in public, advice on this matter varies for patients with acute myeloid leukemia.
Conclusions: The survey demonstrates that there is a wide variation in recommendations on non-pharmacological anti-infective measures between different institutions, countries and continents. This information may be used to encourage harmonization of supportive care practices and future clinical trials.
Diagnostic approaches for invasive aspergillosis—specific considerations in the pediatric population
(2018)
Invasive aspergillosis (IA) is a major cause of morbidity and mortality in children with hematological malignancies and those undergoing hematopoietic stem cell transplantation. Similar to immunocompromised adults, clinical signs, and symptoms of IA are unspecific in the pediatric patient population. As early diagnosis and prompt treatment of IA is associated with better outcome, imaging and non-invasive antigen-based such as galactomannan or ß-D-glucan and molecular biomarkers in peripheral blood may facilitate institution and choice of antifungal compounds and guide duration of therapy. In patients in whom imaging studies suggest IA or another mold infection, invasive diagnostics such as bronchoalveolar lavage and/or bioptic procedures should be considered. Here we review the current data of diagnostic approaches for IA in the pediatric setting and highlight the major differences of performance and clinical utility of the tests between children and adults.
Invasive mold disease (IMD) of the central nervous system (CNS) is a severe infectious complication in immunocompromised patients, but early microbiological diagnosis is difficult. As data on the value of biomarkers in the CNS are scarce, in particular in children, we retrospectively analyzed the performance of galactomannan (GM) and PCR assays in CNS samples of 15 children with proven and probable CNS IMD and of 32 immunocompromised children without fungal infection. Galactomannan in the cerebrospinal fluid (CSF) was assessed in nine of the 15 pediatric patients and was positive in five of them. Polymerase chain reaction (PCR) was performed in eight of the 15 patients and detected nucleic acids from molds in six patients. Galactomannan and PCR in CNS samples were the only positive microbiologic parameter in the CNS in three and two patients, respectively. In four patients, PCR specified the pathogen detected in microscopy. Galactomannan and PCR results remained negative in the CSF of all immunocompromised children without evidence for CNS IMD. Our data suggest that GM and PCR in CNS specimens are valuable additional tools in diagnosing CNS IMD and should be included in the work up of all pediatric patients with suspected mold disease of the CNS.